# EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/EYPT
## Company Profile
- Ticker: EYPT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Ophthalmology
## Stock Data
- Close: 12.83 USD
- Market cap: 1050531463.9399999 USD
- Last updated: 2026-08-06
## Business Overview
### Retinal Disease Focus
EyePoint Pharmaceuticals develops sustained-delivery therapies for serious retinal diseases. Its programs are designed to reduce the treatment burden associated with frequent intravitreal injections while maintaining durable control of retinal vascular disease.
### DURAVYU Technology
DURAVYU combines vorolanib, a selective tyrosine kinase inhibitor, with EyePoint’s bioerodible Durasert E delivery technology. The product candidate is designed to provide extended intraocular drug exposure and inhibit multiple pathways involved in retinal disease.
### Wet AMD Pivotal Program
The identical LUGANO and LUCIA Phase 3 trials evaluate DURAVYU against on-label aflibercept in wet age-related macular degeneration. This program represents the company’s nearest major efficacy readout and follows supportive Phase 2 findings from DAVIO 2.
### Diabetic Macular Edema Expansion
EyePoint is also evaluating DURAVYU in the COMO and CAPRI Phase 3 trials for diabetic macular edema. The studies extend the same sustained-delivery platform into another large retinal market and use six-month redosing.
## Why The Stock Is Moving

Following the latest company update, “EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments”, EYPT closed up 4.97% at $12.25 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Topline results from the Phase 3 LUGANO wet AMD trial expected beginning in mid-2026, followed by results from LUCIA.
- Completion of enrollment in the COMO and CAPRI Phase 3 DME trials expected in the third quarter of 2026.
- Topline results from the Phase 3 DME program anticipated in the fourth quarter of 2027.

## Recent News
- 2026-08-05 11:00 EST — [EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments](https://biopharmsignal.com/news/EYPT/eyepoint-reports-second-quarter-2026-financial-results-and-highlights-recent-cor-6ef36797) — Source: EyePoint Pharmaceuticals
- 2026-07-30 11:00 EST — [EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)](https://biopharmsignal.com/news/EYPT/eyepoint-completes-enrollment-of-both-pivotal-phase-3-trials-of-duravyu-for-trea-38a1e114) — Source: EyePoint Pharmaceuticals
- 2026-07-16 11:00 EST — [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-daeb0fac) — Source: EyePoint Pharmaceuticals
- 2026-07-13 11:00 EST — [EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer](https://biopharmsignal.com/news/EYPT/eyepoint-appoints-tarek-s-hassan-m-d-as-chief-strategic-science-officer-4900131f) — Source: EyePoint Pharmaceuticals
- 2026-05-19 11:00 EST — [EyePoint Announces Participation at Upcoming Investor Conferences](https://biopharmsignal.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-cef7e0be) — Source: EyePoint Pharmaceuticals